Loading...

Galapagos NV

GLPGFPNK
Healthcare
Biotechnology
$33.45
$0.00(0.00%)

Galapagos NV (GLPGF) Financial Performance & Income Statement Overview

Explore the financials of Galapagos NV (GLPGF), including yearly and quarterly data on income, cash flow, and balance sheets.

Revenue Growth
14.99%
14.99%
Operating Income Growth
-113.38%
113.38%
Net Income Growth
-65.01%
65.006%
Operating Cash Flow Growth
21.17%
21.17%
Operating Margin
-120.74%
120.74%
Gross Margin
87.59%
87.59%
Net Profit Margin
-103.14%
103.14%
ROE
-10.20%
10.20%
ROIC
-9.74%
9.74%

Galapagos NV (GLPGF) Income Statement & Financial Overview

View the income breakdown for Galapagos NV GLPGF across both annual and quarterly reports.

MetricQ1 2025Q4 2024Q3 2024Q2 2024
Revenue$74.98M$75.50M$59.85M$77.87M
Cost of Revenue$13.73M$15.74M$19000.00$16.56M
Gross Profit$61.25M$59.76M$59.83M$61.32M
Gross Profit Ratio$0.82$0.79$1.00$0.79
R&D Expenses$182.75M$97.19M$93.05M$73.61M
SG&A Expenses$43.80M$3.69M$46.58M$33.14M
Operating Expenses$219.96M$122.48M$114.14M$106.75M
Total Costs & Expenses$233.69M$138.22M$114.15M$123.31M
Interest Income$12.56M$17.22M$23.13M$23.71M
Interest Expense$780000.00-$499000.00$695000.00$285000.00
Depreciation & Amortization$0.00$0.00$5.86M$4.28M
EBITDA-$158.71M$19.13M-$48.45M$4.97M
EBITDA Ratio-$2.12$0.25-$0.81$0.06
Operating Income-$158.71M-$62.72M-$54.30M-$45.43M
Operating Income Ratio-$2.12-$0.83-$0.91-$0.58
Other Income/Expenses (Net)$2.34M$81.75M$5.16M$42.27M
Income Before Tax-$156.37M$19.03M-$49.14M$4.09M
Income Before Tax Ratio-$2.09$0.25-$0.82$0.05
Income Tax Expense-$1.81M-$93000.00-$571000.00-$571000.00
Net Income-$153.40M$25.31M-$50.43M$8.98M
Net Income Ratio-$2.05$0.34-$0.84$0.12
EPS-$2.33$0.29-$0.77$0.14
Diluted EPS-$2.33$0.38-$0.77$0.14
Weighted Avg Shares Outstanding$65.84M$87.55M$65.90M$65.90M
Weighted Avg Shares Outstanding (Diluted)$65.84M$66.03M$65.90M$65.90M

Financial performance has remained strong, with revenue growing from $77.87M in Q2 2024 to $74.98M in Q1 2025. Gross profit continued to perform well, with margins at 82% in the latest quarter. Operating income reached -$158.71M in Q1 2025, holding a steady -212% margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at -$158.71M. Net income dropped to -$153.40M, keeping EPS at -$2.33. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.

Unlock 25+ Years of Financial Data

Get access to extended historical data, advanced metrics, and more with our premium plan

Frequently Asked Questions

;